Identification of Biomarkers Including 18fdg-Pet/Ct for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Clinical Cancer Research- United States

doi 10.1158/1078-0432.ccr-15-0384

Full Text

Abstract

Available in

Date

Authors

Publisher

American Association for Cancer Research (AACR)

Related search

[18f]ml-10 PET Imaging Fails to Assess Early Response to Neoadjuvant Chemotherapy in a Preclinical Model of Triple Negative Breast Cancer

EJNMMI Research
Nuclear MedicineRadiologyImaging
2020English

Role of 18FDG PET/CT in Breast Cancer

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
Medicine
2018English

Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer

Journal of Medical – Clinical Research & Reviews
2019English

A Comparison of Near-Infrared Diffuse Optical Imaging and 18f-FDG PET/CT for the Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Early Metabolic Response Using FDG PET/CT and Molecular Phenotypes of Breast Cancer Treated With Neoadjuvant Chemotherapy

BMC Cancer
Cancer ResearchOncologyGenetics
2011English

Now Is the Time to Use FDG-PET/CT to Optimize Neoadjuvant Treatment in Triple Negative Breast Cancer!

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Comparative Analysis of Different Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer

Tumors of female reproductive system
2017English

Identification of New Prognostic Biomarkers for Triple Negative Breast Cancer

English

Neoadjuvant Chemotherapy in Breast Cancer: Prediction of Pathologic Response With PET/CT and Dynamic Contrast-Enhanced MR Imaging—Prospective Assessment

Radiology
Nuclear MedicineRadiologyImaging
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy